StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.34−0.06 (-4.61%)

Close on Nov 18, 2026Market cap $1.36MP/E –Yield –

Transcode Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Transcode Therapeutics

Transcode Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Transcode Therapeutics figures

See a number that looks wrong?